Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529516 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,252
- Enrollment target
NCT00529516 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,252 participants.
The verdict
NCT00529516, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,252 participants
- Enrollment target
Study Summary
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this observer blind study, the subjects previously enrolled in study 104888 (NCT00377585) will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104888 (NCT00377585) are eligible for participation in this study.
Interventions
- BIOLOGICAL Fluarix
- BIOLOGICAL GSK Biologicals Influenza Vaccine GSK576389A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,252 participants |
| Start Date | 2007-10-15 |
| Est. Completion | 2008-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529516
The ClinicalTrials.gov registry entry for NCT00529516 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluarix is the first listed.
NCT00529516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529516 about?
NCT00529516 is a clinical study titled "Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults". Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this observer blind study, the sub...
What is the current status of trial NCT00529516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,252 participants. The study started on 2007-10-15. Estimated completion is 2008-06-04.
What interventions are being tested in trial NCT00529516?
The interventions under investigation include: Fluarix (BIOLOGICAL), GSK Biologicals Influenza Vaccine GSK576389A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00529516?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.